Effects of Different Pain Relievers and Dosages on Cognitive Retention

Navya Hooda   Mohammed Yusuf Shaikh   Shivank Goel

Vanshika Vanshika   Jena Shah

April 9, 2025

Painkillers are commonly used to manage pain and their effects are often associated with physical relief. While they provide immediate physical comfort, their impact on cognitive performance is often overlooked. This study explores how different painkillers and dosages influence cognitive function. Using simulated testing from a virtual population, participants were randomly assigned a treatment (drug type and dosage) while controlling for variables such as age. Our findings indicate no significant relationship between drug type, dosage, and overall cognitive performance post-treatment. However, we observed some correlation between certain drug-dosage combinations and memory improvement, suggesting a potential area for further research. While the results were not statistically significant, this study contributes to a deeper understanding of the cognitive effects of painkillers and highlights the need for further investigation into their potential impact on memory and cognition.

Table of contents

1 Acknowledgements

2 Introduction

Pain can make everyday tasks harder, particularly when mental focus and clarity are required. Study has shown that individuals with pain tend to have cognitive dysfunction symptoms (Hu 2009). Common pain relievers like Aspirin, Paracetamol, and Tramadol are often used to reduce physical discomfort, but their impact on cognitive functions are not well understood. Memory retention is a process that requires mental effort – which becomes more difficult when we are in pain. This study investigates how different pain relievers (Aspirin, Paracetamol, and Tramadol) at standard dosages affect memory performance. We will also take a look at how the interaction between drug type and dosage level influence memory function. Understanding how pain relief might impact cognitive performance is important since the ability to recall information is a basis for optimized human function.

2.1 Research Questions

Our study consists of the following research questions.

Research Question 1. *How does the type of pain reliever (Aspirin 500 mg, Paracetamol 500 mg, Tramadol 50 mg, and Placebo) affect memory game performance?*

- Null Hypothesis: All pain relievers at normal dosages act the same for cognitive retention game performances.
- Alternative Hypothesis: There exists at least one pair of distinct pain relievers at normal dosages which act differently for cognitive retention game performances.

Research Question 2. *Is there an interaction effect between the type of pain reliever and dosage level on the improvement in memory game performance?*

- Null Hypothesis: There is no interaction effect between the type of pain reliever and dosage level on the improvement in memory task performance.
- Alternative Hypothesis: There is an interaction effect between at least one of the types of pain reliever and dosage level on the improvement in memory task performance.

The structure of this paper is as follows. Section 3 outlines our data and methodology. Section 4 presents our findings into graphs and charts to visualize the data better. Section 5 presents our quantitative analysis. In Section 6, we discuss the results and address our findings. We end off, we have the limitations and conclusion in Section 7 and Section 8, respectively. All of the code used for this study can be found in Section 9. The references are found in Section 9.

3 Methodology

This study followed all four principles of experimental design: **Control, Block, Randomization and Replication**.

In February, our group members collected observations from participants belonging to a virtual population to assess whether the treatment had any effect on memory performance, this resulted in a total of 240 observations. Each participant was **randomly** assigned a treatment.

The experiment utilized a two-way ANOVA design, where the experimental unit was the participant, the explanatory variables were the type of painkiller and dosage level (low/high), and the response variable was the memory performance, measured by the memory game score.

3.1 Study Design and Treatments

We selected three brands of painkillers: Aspirin, Paracetamol, and Tramadol. Additionally, we considered a placebo treatment. As a result, this study involves 2 factors: pain reliever type (4 levels - Aspirin, Paracetamol, Tramadol, Placebo) and dosage (2 levels - Low, High). Crossing the two factors provides us with a total of *8 treatment groups*, with **30 participants** assigned to each. The total crossed treatment groups are shown in Table 1.

This results in **240 total observations** ($8 \times 30 = 240$).

For each treatment, we selected 30 different people (n = 30). Through randomly picking the virtual citizens, we **replicated** 30 experimental units per treatment. The even observations per treatment group ensures we have a **balanced design**.

Table 1: Treatment Groups

Dosage	Aspirin	Paracetamol	Tramadol	Placebo
		Drug Type		
Low	Aspirin 500 mg	Paracetamol 500 mg	Tramadol 50 mg	Placebo 1 Tablet
High	Aspirin 1000 mg	Paracetamol 1000 mg	Tramadol 100 mg	Placebo 2 Tablets

3.1.1 Nuisance Variable: Age

To reduce bias, we consider **controlling** the experiment by limiting participant ages to be strictly 18+. Hence in this study, **age** acts as a **nuisance variable**. We also used **blocking** for age by ensuring participants were categorized into three even groups to prevent bias created through age. Table 2 shows the breakdown of the groups.

3.2 Quantitative and Qualitative Variables

In our study the quantitative and qualitative variables are as follows:

1. Quantitative variables: Memory Game Scores
2. Qualitative variables: Type of pain reliever, dosage level (low/high)

Table 2: Summary of Age Groups

Age Group	Count	Percentage
18-34	80	33.33
35-50	80	33.33
50+	80	33.33

Table 3: Summary Statistics for Quantitative Variables

Statistic	Memory Game Score
Mean	62.57583
Median	61.50000
SD	15.63703
IQR	23.35000

Table 4: Summary of Drug Types

Drug	Count	Percentage
Aspirin	60	25
Paracetamol	60	25
Placebo	60	25
Tramadol	60	25

3.3 Summary of quantitative variables

Table 3 shows the summary statistics of the treatment memory game scores. The mean memory game score is 62.58 seconds, with a median of 61.50 seconds, which indicates that the distribution is fairly symmetric.

Table 5: Summary of Dosage Levels

Dosage	Count	Percentage
High	120	50
Low	120	50

3.4 Summary of counts and percentage for qualitative variables

Table 4 shows the distribution of participants across drug types. Aspirin, Paracetamol, and Tramadol, and Placebo each have 60 participants (25%), ensuring balance.

Table 5 shows the dosage levels assigned to participants. There is an equal split between high-dose (120 participants, 50%) and low-dose (120 participants, 50%) conditions.

3.5 Confounding Variable

Table 2 shows the breakdown of age groups, which is a confounding variable in this study. The three age groups: 18–34, 35–50, and 50+ each have 80 participants (33.33%).

4 Plots

Figure 1: Interaction and Boxplots for Drug and Dosage Effects

Figure 1 shows the distribution of memory game scores across different drug types using box plots and interaction plot.

From the box plots, we observe:

1. The median memory game scores are relatively similar across most drug types.
2. Tramadol (high dosage) shows a higher median score compared to other treatments.
3. The Placebo group has a slightly lower median score than the others.
4. The interquartile range (IQR) is consistent across all groups, although Tramadol (high dosage) has slightly more variability.

The interaction plot suggests an interaction effect between drug type and dosage level, as the lines are not parallel. The low-dosage line shows a sharp increase in memory scores for Tramadol and a dip for Placebo. However, the high-dosage line follows a more gradual trend. This indicates that the effect of dosage on memory performance may depend on the type of pain reliever administered.

Although the visual pattern indicates potential interaction, a formal Two-Way ANOVA is required to determine the statistical significance of this relationship.

Table 6: Shapiro-Wilk Test for Normality

	Statistic	P-Value	Method
W	0.9886	0.0555	Shapiro-Wilk normality test

5 Analysis

5.1 Assumption Checks

The method of two-way ANOVA is used to estimate the mean of memory game score changes according to the levels of two categorical variables that are drug and dosage level. Before performing the Two-Way ANOVA, we verified the assumptions of the model as seen from using Q-Q plot as seen in Figure 2.


Figure 2: Q-Q Plot of Residuals

The Shapiro-Wilk Test confirms a p-value $= 0.05553$ as per Table 6, so we fail to reject the null hypothesis and the result confirms that the dataset is *normally distributed*.

Our second assumption of Homogeneity of Variance appears to be satisfied. As shown in the Figure 3, the spread of the residual remains relatively consistent across the of fitted values. Further the result of the Bartlett test for homogeneity of variances from Table 7, suggests the p-value is 0.3346. Since this p-value is greater than the 0.05 significance level, we fail to reject the null hypothesis of equal variances. Hence, the assumption is verified. Lastly, for our

Table 7: Bartlett's Test for Homogeneity of Variance

	Statistic	DF	P-Value	Method
Bartlett's K-squared	7.9776	7	0.3346	Bartlett test of homogeneity of variances

two-way ANOVA model, the different combinations of pain reliever type and dosage levels, the treatments were randomly assigned to all participants which ensures *independence.*

Figure 3: Residual plot: Check for Homoscedasticity

5.2 Model

The method of Two-way ANOVA is used to estimate the mean of a memory game score changes according to the levels of two categorical variables that is drug and dosage level. The general statistical form of the model is:

$$Y_{ijk} = \mu + \alpha_i + \beta_j + (\alpha\beta)_{ij} + \varepsilon_{ijk}$$

Where

- Y_{ijk}: Memory score for the k-th participant receiving the i-th drug and j-th dosage level

- μ: Overall mean

- α_i: Effect of the i-th drug (Aspirin, Tramadol, Paracetamol, Placebo)
- β_j: Effect of the j-th dosage level (High Dosage, Low dosage)

- $(\alpha\beta)_{ij}$: Interaction effect between drug and dosage

- $\epsilon_{ijk} \sim N(0, \sigma^2)$: Random error

In this analysis where our focus in on Two-Way ANOVA Model and so we fit using linear regression model using dummy variable coding using Treatment Aspirin-High dosage as the baseline group. The aim is to interpret estimated coefficients relative to reference group. The model we used in our analysis can be expressed as:

$$Y_i = \beta_0 + \beta_1 \cdot \text{Paracetamol}_i + \beta_2 \cdot \text{Placebo}_i + \beta_3 \cdot \text{Tramadol}_i$$
$$+ \beta_4 \cdot \text{LowDosage}_i + \beta_5 \cdot (\text{Paracetamol}_i \times \text{LowDosage}_i)$$
$$+ \beta_6 \cdot (\text{Placebo}_i \times \text{LowDosage}_i) + \beta_7 \cdot (\text{Tramadol}_i \times \text{LowDosage}_i) + \varepsilon_i$$

Where

- β_0: Intercept (Aspirin at High dosage — the reference group)

- $\beta_1, \beta_2, \beta_3$: Main effects of Paracetamol, Placebo, and Tramadol relative to Aspirin

- β_4: Effect of Low dosage relative to High

- $\beta_5, \beta_6, \beta_7$: Interaction effects for each drug under Low dosage

- ϵ_i: Residual error for the i-th participant

The Intercept term β_0 accounts for the reference group. All other coefficients β_j represent the mean difference between the specified group and the reference group, holding other factors constant for j = *1, 2, 3, 4, 5, 6, 7*

The Table 8 show the intercept ($\beta_0 = 62.20$) is the average memory game score for individuals given High dosage and Aspirin Drug (reference group). While comparing other treatments to reference level, we observe most coefficients from Table 8 are not statistically significant at 5% level. The coefficient of Drug Paracetamol ($p-value = 0.9927$), Tramadol ($p-value = 0.5281$), Placebo ($p-value = 0.3893$) indicates that mean memory game scores for these groups are not statistically different from the reference group. Similarly, the evidence for all the Interaction terms suggests no statistical significance between drug type and dosage level has any effect on the memory game score performance as p value are greater than 5% significance level. The

Table 8: Coefficient Estimates from Linear Model for Memory Game Score

Predictor Term	Estimate	Std. Error	t-statistic	p-value
(Intercept)	62.2000000	2.839371	21.9062572	0.0000000
drugParacetamol	0.0366667	4.015478	0.0091313	0.9927222
drugPlacebo	3.4633333	4.015478	0.8624960	0.3893053
drugTramadol	2.5366667	4.015478	0.6317223	0.5281903
dosage_levelLow	-2.1800000	4.015478	-0.5428993	0.5877203
drugParacetamol:dosage_levelLow	1.2900000	5.678743	0.2271630	0.8204971
drugPlacebo:dosage_levelLow	-6.5166667	5.678743	-1.1475545	0.2523345
drugTramadol:dosage_levelLow	4.8800000	5.678743	0.8593451	0.3910372

Table 9: Model Summary Statistics for Memory Game Score

R - sqaured	F-Statistic	Model df	Residual df	p-value	Residual Std. Error	Sample Size (n)
0.0398318	1.374906	7	232	0.216744	15.55188	240

lack of significance indicates that the effect of dosage does not vary meaningfully across drug types and dosage levels, indicating an absence of interaction between the two factors.

6 Discussion

6.1 Interpretation of Results

The two-way ANOVA results Table 10 revealed no statistically significant main effects of drug type ($p = 0.25$) or dosage level ($p = 0.26$) on memory game scores, as both p-values exceed the 0.05 threshold.

For **Research Question 1**, which asked whether the type of pain reliever impacts memory performance, we found no significant differences in memory scores between the drug groups

Table 10: Two-Way ANOVA Results for Memory Game Score

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	3	1000.7542	333.5847	1.379242	0.2498211
dosage_level	1	308.2667	308.2667	1.274562	0.2600786
drug:dosage_level	3	1018.7310	339.5770	1.404018	0.2423452
Residuals	232	56111.7280	241.8609	NA	NA

(Aspirin, Paracetamol, Tramadol, or Placebo). Therefore, we fail to reject the null hypothesis for Research Question 1.

Similarly, the **interaction effect** between drug type and dosage level was not statistically significant ($p = 0.24$), suggesting that the impact of drug type on memory retention does not vary by dosage level. This directly addresses **Research Question 2**, and we again fail to reject the null hypothesis, concluding that there is no interaction effect between the type of pain reliever and dosage on memory task performance.

Since no interaction effect was present, we examined the main effects independently. As mentioned, drug type was not significant, and neither was **dosage level** ($p = 0.26$), indicating that neither factor significantly influenced cognitive performance.

The lack of statistically significant findings persisted even after **controlling for age** as a potential confounding variable. Participants were stratified into balanced age groups (18–34, 35–50, and 50+ years) to minimize age-related bias.

6.2 Effect Size and Power Analysis

Since the interaction effect was not statistically significant ($p > 0.05$), we proceeded to assess the effect size with the purpose to evaluate the practical significance of our findings. Our model yields $R^2 = 0.0398$. While R^2 is commonly used in regression analysis to measure the proportion of variance and goodness of fit of the model, it can also be applied into ANOVA models. In that case, the R^2 value shows how much of the variation in the results can be explained by the different groups. However, it doesn't tell us how big or important the differences between the groups actually are.

We use this R^2 value to report the effect that corresponds to Cohen's f guidelines, i.e. $|f|$ is about 0.20 since our R^2 falls between the small-medium categories. Even though the statistical test did not yield significant results, this quantity suggests we have approximately a small-medium effect size, indicating that the type of drug and dosage level may still have had a meaningful impact on memory task performance.

We did a post-hoc power analysis. Based on our two-way ANOVA model, we calculated the power for the two main effects and the interaction effect (ie. drug, dosage_level, and drug:dosage_level, respectively).

We achieved the following effect sizes (Cohen's f) and powers. For drug type, we got the effect size of 0.134 and a power of 37.6%. For the dosage level, we got the effect size of 0.074 and a power of 20.8%. And for the interaction effect for the drug and dosage level, we got the effect size of 0.135 and a power of 38.2%.

These results show that the statistical power for all three effects were low. In other words, our study had a limited ability to detect real effects, should they exist. With power values

of 37.6%, 20.8%, and 38.2% for the drug, dosage level, and interaction effects respectively, we had less than a 40% chance of identifying a true effect under the conditions of our study.

This suggests that while our ANOVA results were not statistically significant – possibly due to insufficient power rather than the absence of any real effect. The observed effect sizes fall into the small range according to Cohen's conventions, which typically require a larger sample size to detect reliably.

We discuss about addressing this limitation in the next section.

7 Limitations

Our study is overall focused on memory, which may have links to one's education and IQ level, as they are all related to mental function and cognition. In the future, we could test everyone for IQ scores and their highest level of education – these two nuisance variables can be taken care of by using the four principles of experimental design. Additionally, we used 30 observations for each treatment group which may not be large enough. We can increase this number for future studies. To add on, not all participants were in pain, so the efficacy of the improvement of pain killers may be biased and using a virtual population may not ensure whether this aspect could be captured. Lastly, cognitive retention was measured immediately post-treatment – the long term impacts are not yet explored. To improve our study, we can try to consider individuals with real pain symptoms before the study to ensure a reduction of bias, and provide a realistic test setting. Additionally, carrying the experiment out in the long-term would help with understanding the effects of painkillers and dosages on memory.

There's also a chance that the participants' expectations influenced their results if they knew which treatment they were getting (we cannot expand on this as it was a virtual experiment). In the future, bias could be minimized through having a double-blind design in which neither the participants nor the researchers know who's getting what. We only tested low and high dosages, so we might be missing more subtle effects that show up with intermediate doses. So if we were to include a wider range of dosages in future studies, it could give a fuller picture. Another issue is that our sample might not fully represent the general population since we selected participants from specific clusters of locations – not all locations were covered equally. This means our findings might not apply to everyone. Next time, we could choose more diverse and evenly spread-out clusters to make the results more general. Lastly, despite our efforts to control for confounding factors, there are still some variables (like sleep quality, stress levels, or baseline cognitive function) that could affect memory performance. Being more thorough in accounting for these factors could improve the accuracy of the results.

8 Conclusion

This study did not find clear evidence that pain relievers or their dosages have a significant impact on cognitive retention. However, the exploratory trends observed, particularly with Paracetamol and Tramadol, highlight the need for larger-scale studies to investigate subtle or context-dependent effects. Future research could incorporate longitudinal designs, broader age-specific analyses, and alternative cognitive metrics to deepen understanding of painkillers' cognitive implications.

9 Appendix

```r
library(knitr)
library(kableExtra)

# Create a dataframe for the table
study_table <- data.frame(
  Dosage = c("Low", "High"),
  Aspirin = c("Aspirin 500 mg", "Aspirin 1000 mg"),
  Paracetamol = c("Paracetamol 500 mg", "Paracetamol 1000 mg"),
  Tramadol = c("Tramadol 50 mg", "Tramadol 100 mg"),
  Placebo = c("Placebo 1 Tablet", "Placebo 2 Tablets")
)

# Render the table
kable(study_table, align = "c") %>%
  add_header_above(c(" " = 1, "Drug Type" = 4)) %>%
  kable_styling(full_width = FALSE, position = "center")
```

	Drug Type			
Dosage	Aspirin	Paracetamol	Tramadol	Placebo
Low	Aspirin 500 mg	Paracetamol 500 mg	Tramadol 50 mg	Placebo 1 Tablet
High	Aspirin 1000 mg	Paracetamol 1000 mg	Tramadol 100 mg	Placebo 2 Tablets

```r
library(tidyverse)
library(janitor)
library(here)
library(lubridate)
library(patchwork)
library(arrow)
library(effectsize)
library(dplyr)
library(knitr)
library(performance)
library(modelsummary)
library(kableExtra)
library(performance)
library(WebPower)
```

```
Loading required package: MASS


Attaching package: 'MASS'

The following object is masked from 'package:patchwork':

    area

The following object is masked from 'package:dplyr':

    select

Loading required package: lme4

Loading required package: Matrix


Attaching package: 'Matrix'

The following objects are masked from 'package:tidyr':

    expand, pack, unpack

Loading required package: lavaan

This is lavaan 0.6-19
lavaan is FREE software! Please report any bugs.

Loading required package: parallel

Loading required package: PearsonDS
```

```r
library(ggpubr)


clean_data <- read.csv(here("data", "analysis_data", "clean_data.csv"))
```

```
age_counts <- table(clean_data$age_group)

# percentages for each age group
age_percentages <- prop.table(age_counts) * 100

# summary dataframe
age_summary <- data.frame(
  `Age Group` = names(age_counts),
  Count = as.numeric(age_counts),
  Percentage = round(as.numeric(age_percentages), 2)
)

colnames(age_summary)[colnames(age_summary) == "Age.Group"] <- "Age Group"

# Display table
kable(age_summary, booktabs = TRUE, row.names = FALSE)
```

Age Group	Count	Percentage
18-34	80	33.33
35-50	80	33.33
50+	80	33.33

```
mean_game <- mean(clean_data$memory_game_score, na.rm = TRUE)
median_game <- median(clean_data$memory_game_score, na.rm = TRUE)
sd_game <- sd(clean_data$memory_game_score, na.rm = TRUE)
iqr_game <- IQR(clean_data$memory_game_score, na.rm = TRUE)

# Create summary table with clean column header
summary_table <- data.frame(
  Statistic = c("Mean", "Median", "SD", "IQR"),
  "Memory Game Score" = c(mean_game, median_game, sd_game, iqr_game),  check.names = FALSE
)

# Display table
kable(summary_table, format = "latex", booktabs = TRUE)
```

Statistic	Memory Game Score
Mean	62.57583
Median	61.50000
SD	15.63703
IQR	23.35000

```r
drug_counts <- table(clean_data$drug)

# percentages
drug_percentages <- prop.table(drug_counts) * 100

#  summary dataframe
drug_summary <- data.frame(
  Drug = names(drug_counts),
  Count = as.numeric(drug_counts),
  Percentage = round(as.numeric(drug_percentages), 2)
)

# Display table
kable(drug_summary, format = "latex", booktabs = TRUE)
```

Drug	Count	Percentage
Aspirin	60	25
Paracetamol	60	25
Placebo	60	25
Tramadol	60	25

```r
p3 <- ggplot(clean_data, aes(x = drug, y = memory_game_score, fill = dosage_level)) +
  geom_boxplot() +
  labs(x = "Drug Type", y = "Memory Game Score", fill = "Dosage Level") +
  theme_minimal()
```

```r
p1 <- ggplot(clean_data, aes(x = drug, y = memory_game_score, color = dosage_level, group = 
  stat_summary(fun = mean, geom = "point", size = 2) +
  stat_summary(fun = mean, geom = "line", size = 1) +
  labs(title = "Memory Game Scores",
       x = "Drug Type",
       y = "Mean Memory Game Score",
       color = "Dosage Level") +
  theme_minimal()
```

```
# Combine the plots side by side
p1 + p3
```

Memory Game Scores


```
clean_data$dosage_level <- factor(clean_data$dosage_level, levels = c("Low", "High"))

# Boxplot of Memory Game Scores by Drug, colored by Dosage Level
ggplot(clean_data, aes(x = drug, y = memory_game_score, fill = dosage_level)) +
  geom_boxplot() +
  labs(
    x = "Drug Type",
    y = "Memory Game Score",
    fill = "Dosage Level"
  ) +
  theme_minimal() +
  theme(
    plot.title = element_text(size = 14, face = "bold"),
    axis.title = element_text(size = 12)
  )
```

```
ggplot(clean_data, aes(x = drug, y = memory_cards_score, fill = dosage_level)) +
  geom_boxplot() +
  labs(
    x = "Drug Type",
    y = "Memory Cards Score",
    fill = "Dosage Level"
  ) +
  theme_minimal()
```

term	estimate	std.error	statistic	p.value
(Intercept)	60.020000	2.839371	21.1384816	0.0000000
drugParacetamol	1.326667	4.015478	0.3303883	0.7414048
drugPlacebo	-3.053333	4.015478	-0.7603911	0.4477929
drugTramadol	7.416667	4.015478	1.8470198	0.0660176
dosage_levelHigh	2.180000	4.015478	0.5428993	0.5877203
drugParacetamol:dosage_levelHigh	-1.290000	5.678743	-0.2271630	0.8204971
drugPlacebo:dosage_levelHigh	6.516667	5.678743	1.1475545	0.2523345
drugTramadol:dosage_levelHigh	-4.880000	5.678743	-0.8593451	0.3910372

r.squared	adj.r.squared	sigma	statistic	p.value	df	logLik	AIC	BIC	deviance	df.residual	nobs
0.0398318	0.0108612	15.55188	1.374906	0.216744	7	-995.0806	2008.161	2039.487	56111.73	232	240

```r
model_glance <- glance(anova_model)
kable(model_glance, format = "latex", booktabs = TRUE) %>%
    kable_styling(latex_options = "scale_down")
```

```r
# Two way ANOVA result
anova_result <- anova(anova_model)

anova_table_df <- as.data.frame(anova_result)

kable(anova_table_df, format = "latex", booktabs = TRUE)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	3	1000.7542	333.5847	1.379242	0.2498211
dosage_level	1	308.2667	308.2667	1.274562	0.2600786
drug:dosage_level	3	1018.7310	339.5770	1.404018	0.2423452
Residuals	232	56111.7280	241.8609	NA	NA

```r
# Normality Check
ggqqplot(residuals(anova_model))
```


Figure 4: Q-Q Plot of Residuals

```r
#| fig.width: 9
#| fig.height: 8
#| dpi: 300
```

```
#| fig-cap: "Q-Q Plot of Residuals"

# Shapiro-Wilk Normality Test
shapiro_test <- shapiro.test(residuals(anova_model))
shapiro_table <- data.frame(
  Statistic = round(shapiro_test$statistic, 4),
  P_Value = round(shapiro_test$p.value, 4),
  Method = shapiro_test$method
)

kable(shapiro_table, format = "latex", booktabs = TRUE)
```

	Statistic	P_Value	Method
W	0.9886	0.0555	Shapiro-Wilk normality test

```
plot(anova_model, which = 3)
```



```
# EFFECT SIZE AND POWER ANALYSIS
eta_sq <- eta_squared(anova_model, partial = TRUE)

eta2drug <- eta_sq$Eta2[1]
```

```r
cohenfdrug <- sqrt(eta2drug / (1 - eta2drug))
print(cohenfdrug)
```

```
[1] 0.1335478
```

```r
eta2dos <- eta_sq$Eta2[2]
cohenfdos <- sqrt(eta2dos / (1 - eta2dos))
print(cohenfdos)
```

```
[1] 0.07412018
```

```r
eta2drugdos <- eta_sq$Eta2[3]
cohenfdrugdos <- sqrt(eta2drugdos / (1 - eta2drugdos))
print(cohenfdrugdos)
```

```
[1] 0.134742
```

```r
powerdrug <- wp.kanova(
  n = 240,
  ndf = 3,
  f = cohenfdrug,
  ng = 8,
  alpha = 0.05
)

powerdos <- wp.kanova(
  n = 240,
  ndf = 1,
  f = cohenfdos,
  ng = 8,
  alpha = 0.05
)

powerdrugdos <- wp.kanova(
  n = 240,
  ndf = 3,
  f = cohenfdrugdos,
  ng = 8,
  alpha = 0.05
```

```
)
```

```
print(powerdrug)
```

Multiple way ANOVA analysis

```
      n ndf ddf         f ng alpha     power
    240   3 232 0.1335478  8  0.05 0.3759249
```

NOTE: Sample size is the total sample size
URL: http://psychstat.org/kanova

```
print(powerdos)
```

Multiple way ANOVA analysis

```
      n ndf ddf          f ng alpha     power
    240   1 232 0.07412018  8  0.05 0.208078
```

NOTE: Sample size is the total sample size
URL: http://psychstat.org/kanova

```
print(powerdrugdos)
```

Multiple way ANOVA analysis

```
      n ndf ddf        f ng alpha     power
    240   3 232 0.134742  8  0.05 0.3821884
```

NOTE: Sample size is the total sample size
URL: http://psychstat.org/kanova

References

Hu, Yifeng. 2009. "Amitriptyline Rather Than Lornoxicam Ameliorates Neuropathic Pain-Induced Deficits in Abilities of Spatial Learning and Memory." *European Journal of Anaesthesiology.* https://journals.lww.com/ejanaesthesiology/FullText/2010/02000/Amitriptyline_rather_than_lornoxicam_ameliorates.6.aspx.